AR030179A1 - Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico - Google Patents

Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico

Info

Publication number
AR030179A1
AR030179A1 ARP000106887A ARP000106887A AR030179A1 AR 030179 A1 AR030179 A1 AR 030179A1 AR P000106887 A ARP000106887 A AR P000106887A AR P000106887 A ARP000106887 A AR P000106887A AR 030179 A1 AR030179 A1 AR 030179A1
Authority
AR
Argentina
Prior art keywords
receptor
abl
pdgf
product
kit
Prior art date
Application number
ARP000106887A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR030179A1 publication Critical patent/AR030179A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP000106887A 1999-12-27 2000-12-22 Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico AR030179A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI002711A ITMI992711A1 (it) 1999-12-27 1999-12-27 Composti organici

Publications (1)

Publication Number Publication Date
AR030179A1 true AR030179A1 (es) 2003-08-13

Family

ID=11384195

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106887A AR030179A1 (es) 1999-12-27 2000-12-22 Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico

Country Status (18)

Country Link
US (2) US20030125343A1 (https=)
EP (1) EP1250140B1 (https=)
JP (1) JP2003523325A (https=)
CN (1) CN1304005C (https=)
AR (1) AR030179A1 (https=)
AT (1) ATE432069T1 (https=)
AU (1) AU2171901A (https=)
BR (1) BR0016817A (https=)
CA (1) CA2394944A1 (https=)
CO (1) CO5271710A1 (https=)
DE (1) DE60042283D1 (https=)
ES (1) ES2326307T3 (https=)
HK (1) HK1050993A1 (https=)
IT (1) ITMI992711A1 (https=)
PE (1) PE20010991A1 (https=)
PT (1) PT1250140E (https=)
TW (1) TWI246917B (https=)
WO (1) WO2001047507A2 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE369894T1 (de) * 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
EP1408978A4 (en) 2001-06-21 2005-07-13 Ariad Pharma Inc NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
IL161462A0 (en) * 2001-10-25 2004-09-27 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
EP1487451A4 (en) * 2002-03-21 2007-10-03 Dana Farber Cancer Inst Inc Inhibition of Cell Death Responses Induced by OXIDATIVE STRESS
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
AU2007201830C1 (en) * 2002-04-23 2017-09-07 Novartis Pharma Ag High drug load tablet
US20060052387A1 (en) * 2002-06-26 2006-03-09 Marsh Clay B Organic compounds
BR0312821A (pt) * 2002-07-24 2005-04-19 Akira Ohtsuru 4-(4-metil-piperazin-1-il-metil)-n-[(4-metil-3-(4-piridin-3-i l)-pirimidin-2-il-amino)-fenil]-benzamida para tratar câncer anaplásico da tireóide
US7585866B2 (en) * 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
AU2003273675A1 (en) * 2002-10-09 2004-05-04 Wayne R. Danter Protein tyrosine kinase inhibitors
WO2005027910A1 (en) * 2003-08-25 2005-03-31 Dana-Farber Cancer Institute Inc. Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
CA2538523A1 (en) * 2003-09-19 2005-03-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US8048883B2 (en) † 2004-02-11 2011-11-01 Natco Pharma Limited Polymorphic form of imatinib mesylate and a process for its preparation
EP1768982A2 (en) 2004-06-29 2007-04-04 Amgen Inc. Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity
BRPI0514094A (pt) * 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
AU2005322855B2 (en) 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20060275365A1 (en) * 2005-06-07 2006-12-07 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20070059359A1 (en) * 2005-06-07 2007-03-15 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
DE602006015994D1 (de) * 2005-06-23 2010-09-16 Novartis Ag Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
ATE475660T1 (de) 2005-12-21 2010-08-15 Abbott Lab Antivirale verbindungen
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
EP1979348B1 (en) * 2005-12-21 2012-01-18 Abbott Laboratories Anti-viral compounds
EA016611B1 (ru) * 2006-04-20 2012-06-29 Янссен Фармацевтика Н.В. Способ лечения мастоцитоза
EP2043651A2 (en) * 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
JP5571387B2 (ja) 2007-01-11 2014-08-13 クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド 癌の治療のための化合物および方法
US20080248548A1 (en) * 2007-04-09 2008-10-09 Flynn Daniel L Modulation of protein functionalities
BRPI0817946A2 (pt) * 2007-09-25 2015-05-05 Teva Pharma Composições de imatinibe estável
CA2710039C (en) * 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2247596A2 (en) 2008-01-11 2010-11-10 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CA2744563A1 (en) 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
ITRM20090578A1 (it) * 2009-11-10 2011-05-11 Noi Per Voi Onlus Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti.
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
TR201010618A2 (tr) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US20160015708A1 (en) 2012-02-21 2016-01-21 Ranbaxy Laboratories Limited Stable dosage forms of imatinib mesylate
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
KR102529049B1 (ko) 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
AU2020211071A1 (en) 2019-01-23 2021-07-15 Novartis Ag New crystalline forms of a succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US20030069174A1 (en) * 1997-03-10 2003-04-10 Ludwig Pichler Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP1201668A4 (en) * 1999-07-13 2003-05-21 Kyowa Hakko Kogyo Kk Staurosporine DERIVATIVES
EP1382339B1 (en) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives

Also Published As

Publication number Publication date
ATE432069T1 (de) 2009-06-15
ITMI992711A0 (it) 1999-12-27
CN1304005C (zh) 2007-03-14
CO5271710A1 (es) 2003-04-30
PE20010991A1 (es) 2001-10-23
BR0016817A (pt) 2002-10-01
JP2003523325A (ja) 2003-08-05
WO2001047507A3 (en) 2002-04-04
HK1050993A1 (zh) 2003-07-18
PT1250140E (pt) 2009-08-24
WO2001047507A2 (en) 2001-07-05
ES2326307T3 (es) 2009-10-07
CN1414858A (zh) 2003-04-30
DE60042283D1 (de) 2009-07-09
US20090221519A1 (en) 2009-09-03
TWI246917B (en) 2006-01-11
ITMI992711A1 (it) 2001-06-27
EP1250140A2 (en) 2002-10-23
CA2394944A1 (en) 2001-07-05
US20030125343A1 (en) 2003-07-03
EP1250140B1 (en) 2009-05-27
AU2171901A (en) 2001-07-09

Similar Documents

Publication Publication Date Title
AR030179A1 (es) Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico
AR048502A1 (es) Sinergia terapeutica de compuestos anti-cancer
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
GEP20115283B (en) Pyrrolopyrimidine compounds and their uses
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
CL2009000241A1 (es) Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
WO2011031474A3 (en) Use of metformin in cancer treatment and prevention
AR053809A1 (es) Combinacion de compuestos organicos
AR074778A1 (es) Composicion farmaceutica, con anticuerpo monoclonal humano anti - igf-ir.
AR047988A1 (es) Combinaciones antineoplásicas de cci-779 y rituximab
NO20060871L (no) Azepinderivater som farmasoytiske midler
AR044039A1 (es) Combinaciones antineoplasicas
WO2003063787A3 (en) Non-steroidal analogs of 2-methoxyestradiol
CU20090007A6 (es) Un compuesto farmacéutico y un proceso del mismo
CR20190429A (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA-DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
PL342614A1 (en) Anticarcinogenic drugs
WO2022061155A9 (en) Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
Guilhot et al. Significant Higher Rates of Undetectable Molecular Residual Disease and Molecular Responses with Pegylated Form of Interferon a2a in Combination with Imatinib (IM) for the Treatment of Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) Patients (pts): Confirmatory Results at 18 Months of Part 1 of the Spirit Phase III Randomized Trial of the French CML Group (FI LMC).
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
BR0112122A (pt) Composto de rutênio (ii) , uso de um composto, composição farmacêutica, método para tratar e/ou prevenir o câncer, e, processo para preparar um composto
Axelrod et al. The combination of entospletinib and vincristine demonstrates synergistic activity in a broad panel of hematological cancer cell lines and anti-tumor efficacy in a DLBCL xenograft model

Legal Events

Date Code Title Description
FA Abandonment or withdrawal